Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01681693 · ClinicalTrials.gov registry record · Phase 1
Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01681693 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 33 participants.
The verdict
NCT01681693, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01681693
The ClinicalTrials.gov registry entry for NCT01681693 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT01681693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01681693 about?
NCT01681693 is a clinical study titled "Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans". The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, ...
What is the current status of trial NCT01681693?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2010-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01681693?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT01681693?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.